Triomics secures $22 million to enhance cancer treatment AI
Triomics has raised <strong>$22 million</strong> in a Series B funding round led by <strong>Battery Ventures</strong> to develop artificial intelligence technologies for cancer treatment. This investment comes at a crucial time as medical institutions seek to improve treatment outcomes using advanced technology.